CARLSBAD, CA--(Marketwire - Dec 11, 2012) - International Stem Cell Corporation (
On December 13, 2012 Lifeline will host an exclusive media event in New York City to launch the latest product in its line of anti-aging products, the Eye Firming Complex. More than 50 magazine, newspaper and online editors as well as broadcast producers are expected to attend. The event will be hosted by Elizabeth Hale, M.D., one of the nation's top dermatologists and frequent guest on The Dr. Oz Show.
Following the media event, OpenSky, a social shopping marketplace specializing in Beauty, Healthy Living, Food and Style with more than two million subscribers, plans to market and sell Lifeline products. OpenSky, which was named one of the 50 Most Innovative Companies by Fast Company magazine, will use curators including Mariel Hemingway to create a Lifeline shopping circle and personalized shopping experience.
"Open Sky's business model is a simple one, people buy from people that they like. OpenSky uses high profile authors, celebrities and publishers to endorse products both through the e-commerce site as well as through the celebrity's own social network. Lifeline is fortunate to be represented by Mariel Hemingway not only because of her influence and social community -- but because she is an advocate of Lifeline," said Donna Queen, President of Lifeline Skin Care.
To accelerate professional sales, new distributors have been engaged. Spa Care Group, a new division of Spa Equip, one of the largest distributors to the world's most prestigious destination, resort, day, fitness and medical spas, has begun offering Lifeline products to its accounts, including spa owners, directors, developers, and operations consultants. Executive Medicine of Texas, producer of the radio show "Staying Young," which is heard in the Dallas/Fort Worth area as well as on Sirius radio, will be Lifeline's exclusive distributor in Texas for both physicians and spas.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.
To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
Safe harbor statement
Statements pertaining to anticipated marketing and sales developments, the potential uses of our technologies and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects" or "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.